Fund moves

Abbott Laboratories (ABT): Fayez Sarofim & Co reduced its stake -1M shares

Fayez Sarofim & Co reduced its stake in Abbott Laboratories, per its Q2 2026 13F.

3.28M
Shares reported · -1M vs prior quarter
0.70%
Disclosed portfolio weight
$297M
Reported value
Holdings as of
Jun 30, 2026
Filed
Aug 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  2. May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
  3. Jun 12, 2026Congress · 1 personMembers of Congress: 2 purchases
  4. Jun 16, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  5. Jul 2, 2026FDAFDA device clearance: Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP Catheter
  6. Jul 7, 2026Government · Federal Register proposed ruleMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
  7. Jul 8, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  8. Jul 14, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  9. Jul 15, 2026FDAFDA device clearance: EnSite™ X EP System
  10. Jul 16, 2026Company filing · Form 8-K · ResultsReported its results
  11. Jul 17, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  12. Jul 30, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  13. Aug 6, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 39, Notification of Proposed Production Activity; Abbott Laboratories; (Diagnostic Medical Devices); Irving, Texas
  14. Aug 11, 2026InsiderOfficer sold ~$643K of ABT shares in the open market

What came next

  1. Aug 20, 2026FDARecall: Fisher Scientific Sure-Vue Serum/Urine hCG, Model/ Part: FHC-202/23900529, FHC-202/23900528; Beckman Coulter Inc's ICON 25 hCG, Model/ Part: FHC-202/43025; Hen…
  2. Aug 20, 2026FDARecall: Fisher Scientific Sure-Vue Urine hCG, Model/ Part: FHC-102/23900526; Henry Schein, Inc. One Step + Urine Cassette Test, Model/ Part: FHC-102/9004074, FHC-102/9…
  3. Aug 20, 2026FDARecall: McKesson CONSULT hCG Urine Cassette, Model/ Part: FHC-A102/5001; Alere hCG Cassette (20 mIU/mL) in Urine, Model/ Part: FHC-A102/92210; Fisher Scientific Sure-V…
  4. Aug 20, 2026FDARecall: Fisher Scientific Sure-Vue Urine hCG Strip, Model/ Part: FHC-101/23900527; McKesson CONSULT hCG Urine Test Dipstick CLIA Waived, Model/ Part:FHC-101/5000; Henr…
  5. Aug 25, 2026Insider · 1 personInsiders: 2 sales (~$46.2M)
  6. Sep 2, 2026InsiderOfficer sold ~$3K of ABT shares in the open market
  7. Sep 10, 2026FDARecall: Amplatzer Amulet Left Atrial Appendage Occluder Model Numbers 1. 9-ACP2-007-016 2. 9-ACP2-007-018 3. 9-ACP2-007-020 4. 9-ACP2-007-022 5. 9-ACP2-010-025 6. 9-AC…
  8. Sep 17, 2026FDAFDA device clearance: EnSite™ X EP System
  9. Sep 17, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  10. Sep 18, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  11. Sep 23, 2026FDAFDA device clearance: Anti-HCV Next
  12. Oct 2, 2026CongressDisclosed sale of ABT — reported range $50,001 - $100,000
  13. Oct 21, 2026Company filing · Form 8-K · ResultsReported its results
  14. Oct 27, 2026FDAFDA device approval: Amplatzer Paraclose PVL Occluder
  15. Nov 5, 2026InsiderOfficer sold ~$406K of ABT shares in the open market
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

How this filing works

Explore the data

Common questions

What does this filing report about Abbott Laboratories (ABT) stock?

Fayez Sarofim & Co reduced its stake in Abbott Laboratories, per its Q2 2026 13F. Now 3.28M shares, $297M reported value, 0.70% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Jun 30, 2026. Filed: Aug 17, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Abbott Laboratories recently?

For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABT page.

Does this mean ABT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Abbott Laboratories

Everything OQRO holds on this company is on its ABT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data